Published in Science, Public Health Policy and the Law, the research highlights serious concerns about vaccine manufacturing practices, including the lack of inspection for finished vials and the absence of quality control checks for product preservation and storage. Scientists from CHD, including Brian Hooker, Ph.D., chief scientific officer, and Karl Jablonowski, Ph.D., senior research scientist, led the research.

Analysis of 156 vaccine lots finds higher rate of vaccine injury among certain lots
The study analyzed 156 different vaccine lots distributed from December 2020 to April 2022. The researchers tracked where the vaccine was manufactured and where it was distributed, and traced the lots to vaccine injuries reported to the Vaccine Adverse Events Reporting System (VAERS).

The data was not readily available and had to be obtained via Freedom of Information Act request, which was acquired by the Informed Consent Action Network. The analysis uncovered that early batches, particularly those sent to hospitals and government agencies, had higher rates of serious adverse events (SAEs).

Of the 977,542 adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), 455,820 (46.7%) were linked to the Pfizer vaccine. While only 29% of these reports included lot numbers, researchers were able to match 290,835 serious events to specific batches.

The analysis categorized the adverse events in three categories: non-serious, serious, and those that involved death. A non-serious adverse event includes mild allergic reactions (e.g., rash, itching), temporary discomfort or pain at the injection site, mild fever or headache, and fatigue or malaise. A non-serious adverse event indicates that unnecessary harm has been done to the individual's body, but the issue resolved or wasn't life threatening. In the analysis, a total of 78% of the SAEs were non-serious.